Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
15 Jun 2024
15 Jun 2024
Historique:
revised:
25
05
2024
received:
11
04
2024
accepted:
29
05
2024
medline:
15
6
2024
pubmed:
15
6
2024
entrez:
15
6
2024
Statut:
aheadofprint
Résumé
Patients with essential thrombocythemia (ET) are treated with once-daily low-dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short-term Aspirin Regimens in EsSential Thrombocythemia trial showed that twice-daily aspirin dosing restores persistent platelet thromboxane (TX) inhibition. However, the long-term pharmacodynamic efficacy, safety and tolerability of twice-daily aspirin remain untested. We performed a multicenter, randomized, open-label, blinded-endpoint, phase-2 trial in which 242 patients with ET were randomized to 100 mg aspirin twice- or once-daily and followed for 20 months. The primary endpoint was the persistence of low serum TXB
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agenzia Italiana del Farmaco (AIFA), Ministero della Salute
ID : Study FARM12Y8HH
Investigateurs
Valerio De Stefano
(V)
Elena Rossi
(E)
Silvia Betti
(S)
Tommaso Za
(T)
Angela Ciminello
(A)
Francesca Bartolomei
(F)
Denise Soldati
(D)
Giulia De Santis
(G)
Carlo Patrono
(C)
Bianca Rocca
(B)
Giovanna Petrucci
(G)
Duaa Hatem
(D)
Marco Ruggeri
(M)
Alberto Tosetto
(A)
Giuseppe Carli
(G)
Ilaria Nichele
(I)
Stefania Bellesso
(S)
Francesco Rodeghiero
(F)
Andrea Timillero
(A)
Alessandra Iurlo
(A)
Daniele Cattaneo
(D)
Cristina Bucelli
(C)
Silvia Artuso
(S)
Alfredo Dragani
(A)
Mauro Di Ianni
(M)
Paola Ranalli
(P)
Giovanna Summa
(G)
Celeste Santone
(C)
Francesca Palandri
(F)
Nicola Vianelli
(N)
Giuseppe Auteri
(G)
Eloise Beggiato
(E)
Giuseppe Lanzarone
(G)
Miriana Arminio
(M)
Elena Maria Elli
(EM)
Stefania Priolo
(S)
Nora Giello
(N)
Rossella Renso
(R)
Maria Luigia Randi
(ML)
Irene Bertozzi
(I)
Giulia Bogoni
(G)
Alessandro Maria Vannucchi
(AM)
Paola Guglielmelli
(P)
Giuseppe Loscocco
(G)
Francesco Mannelli
(F)
Giacomo Coltro
(G)
Chiara Paoli
(C)
Enrica Ravenda
(E)
Giorgina Specchia
(G)
Francesco Albano
(F)
Alessandra Ricco
(A)
Paola Carluccio
(P)
Marianna Gentile
(M)
Informations de copyright
© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.
Références
Tefferi A, Pardanani A. Essential Thrombocythemia. N Engl J Med. 2019;381(22):2135‐2144.
Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(4):697‐718.
https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf.
Alvarez‐Larran A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low‐risk essential thrombocythemia with a CALR mutation. Haematologica. 2016;101(8):926‐931.
Alvarez‐Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low‐risk essential thrombocythemia. Blood. 2010;116(8):1205‐1210.
Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low‐dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114‐124.
Petrucci G, Giaretta A, Ranalli P, et al. Platelet thromboxane inhibition by low‐dose aspirin in polycythemia vera: ex vivo and in vivo measurements and in silico simulation. Clin Transl Sci. 2022;15:2958‐2970.
Gruppo Italiano Studio Policitemia. Low‐dose aspirin in polycythaemia vera: a pilot study. Br J Haematol. 1997;97(2):453‐456.
Pascale S, Petrucci G, Dragani A, et al. Aspirin‐insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012;119(15):3595‐3603.
Dragani A, Pascale S, Recchiuti A, et al. The contribution of cyclooxygenase‐1 and ‐2 to persistent thromboxane biosynthesis in aspirin‐treated essential thrombocythemia: implications for antiplatelet therapy. Blood. 2009;115(5):1054‐1061.
De Stefano V, Rocca B, Tosetto A, et al. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. Blood Cancer J. 2018;8(6):49.
Rocca B, Tosetto A, Betti S, et al. A randomized double‐blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood. 2020;136(2):171‐182.
Badimon L, Vilahur G, Rocca B, Patrono C. The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. Cardiovasc Res. 2021;117(9):2001‐2015.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391‐2405.
Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26(4):716‐719.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377‐381.
Catella‐Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809‐1817.
Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17(3–4):317‐327.
Ciabattoni G, Maclouf J, Catella F, FitzGerald GA, Patrono C. Radioimmunoassay of 11‐dehydrothromboxane B2 in human plasma and urine. Biochim Biophys Acta. 1987;918(3):293‐297.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003340.pdf.
Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN‐SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401‐408.
Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098‐4103.
Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN landmark survey. BMC Cancer. 2016;16:167.
Hjermstad MJ, Fayers PM, Haugen DF, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manag. 2011;41(6):1073‐1093.
Rabeneck L, Wristers K, Goldstein JL, Eisen G, Dedhiya SD, Burke TA. Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX‐2‐specific inhibitor and traditional NSAID therapy. Am J Gastroenterol. 2002;97(1):32‐39.
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. J Thromb Haemost. 2005;3(4):692‐694.
Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of A. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119‐2126.
Lex A, Gehlenborg N, Strobelt H, Vuillemot R, Pfister H. UpSet: visualization of intersecting sets. IEEE Trans Vis Comput Graph. 2014;20(12):1983‐1992.
Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome‐negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057‐1069.
Patrono C, Rocca B. Measurement of thromboxane biosynthesis in health and disease. Front Pharmacol. 2019;10:1244.
Hultcrantz M, Bjorkholm M, Dickman PW, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population‐based cohort study. Ann Intern Med. 2018;168(5):317‐325.
Chu DK, Hillis CM, Leong DP, Anand SS, Siegal DM. Benefits and risks of antithrombotic therapy in essential Thrombocythemia: a systematic review. Ann Intern Med. 2017;167(3):170‐180.
Born G, Patrono C. Antiplatelet drugs. Br J Pharmacol. 2006;147(Suppl 1):S241‐S251.
Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330(18):1287‐1294.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203697_aspirin_toc.cfm.
Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low‐dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol. 2009;53(8):667‐677.
Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69(1):180‐186.
Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72(6):1177‐1184.
Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non‐steroidal anti‐inflammatory drugs: meta‐analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769‐779.
Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low‐dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373‐2383.
Rade JJ, Barton BA, Vasan RS, et al. Association of thromboxane generation with survival in aspirin users and nonusers. J Am Coll Cardiol. 2022;80(3):233‐250.
Petrucci G, Buck GA, Rocca B, et al. Thromboxane biosynthesis and future events in diabetes: the ASCEND trial. Eur Heart J. 2024;45(15):1355‐1367.
Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long‐term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159‐166.
Loscocco GG, Gesullo F, Capecchi G, et al. One thousand patients with essential thrombocythemia: the Florence‐CRIMM experience. Blood Cancer J. 2024;14(1):10.
Gangat N, Karrar O, Al‐Kali A, et al. One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood Cancer J. 2024;14(1):11.
De Stefano V, Carobbio A, Di Lazzaro V, et al. Benefit‐risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer J. 2018;8(3):25.
De Stefano V, Ruggeri M, Cervantes F, et al. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia. 2016;30(10):2032‐2038.
Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG‐MRT consensus project. Blood. 2013;121(23):4778‐4781.
Mazza GL, Mead‐Harvey C, Mascarenhas J, et al. Symptom burden and quality of life in patients with high‐risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa‐2a: a post‐hoc analysis of the MPN‐RC 111 and 112 trials. Lancet Haematol. 2022;9(1):e38‐e48.
Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood. 2013;121(10):1701‐1711.
Michiels JJ, Berneman Z, Schroyens W, et al. Platelet‐mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin‐responsive and coumadin‐resistant arterial thrombophilia. Platelets. 2006;17(8):528‐544.
Mesa RA, Jamieson C, Bhatia R, et al. NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018. J Natl Compr Cancer Netw. 2017;15(10):1193‐1207.
Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization‐essential thrombocythemia (IPSET‐thrombosis). Blood. 2012;120(26):5128‐5133.